Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06307431 · ClinicalTrials.gov registry record · Phase 2
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
A Phase 2 study of Renal Cell Carcinoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
- 20
- Study locations
NCT06307431 is a Phase 2 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 272 participants, above the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06307431, a Phase 2 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Placebo
- BIOLOGICAL Intismeran autogene
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104) - Duarte
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro - Los Angeles
- UCSF Medical Center at Mission Bay ( Site 0108) - San Francisco
Massachusetts
- Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 0109) - Boston
- Dana-Farber Cancer Institute-GU ( Site 0101) - Boston
Pennsylvania
- Abramson Cancer Center ( Site 0107) - Philadelphia
- Fox Chase Cancer Center ( Site 0111) - Philadelphia
Buenos Aires F.D.
- Instituto Alexander Fleming-Alexander Fleming ( Site 1101) - Buenos Aires
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 1110) - Buenos Aires
New South Wales
- Macquarie University-MQ Health Clinical Trials Unit ( Site 1502) - Macquarie University
- Westmead Hospital ( Site 1501) - Westmead
Connecticut
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0102) - New Haven
New York
- Memorial Sloan Kettering Cancer Center ( Site 0100) - New York
North Carolina
- Duke Cancer Institute ( Site 0106) - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2032-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06307431
The ClinicalTrials.gov registry entry for NCT06307431 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (13% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06307431 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06307431 about?
NCT06307431 is a clinical study titled "A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).". The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus p...
What is the current status of trial NCT06307431?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2024-04-10. Estimated completion is 2032-06-08.
What conditions does trial NCT06307431 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT06307431?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Placebo (BIOLOGICAL), Intismeran autogene (BIOLOGICAL).
Who is sponsoring clinical trial NCT06307431?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06307431 being conducted?
This trial has 20 study locations across California, Connecticut, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.